{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:16:51Z","timestamp":1788409011492,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T00:00:00Z","timestamp":1377561600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/tp.2013.67","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T13:36:25Z","timestamp":1377610585000},"page":"e295-e295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Peripheral and central nervous system inhibition of 11\u03b2-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384"],"prefix":"10.1038","volume":"3","author":[{"given":"D A","family":"Katz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D M","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Basu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M J","family":"Rieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Daszkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Groves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gevorkyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S S","family":"Jhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ereshefsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G J","family":"Marek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,27]]},"reference":[{"key":"BFtp201367_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/cpdd.5","volume":"2","author":"W Liu","year":"2013","unstructured":"Liu W, Katz DA, Locke C, Daszkowski D, Wang Y, Rieser MJ et al. Clinical safety, pharmacokinetics and pharmacodynamics of the 11\u03b2-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers and elderly adults. Clin Pharmacol Drug Dev 2013; 2: 133\u2013151.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"BFtp201367_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1210\/er.2003-0031","volume":"25","author":"JW Tomlinson","year":"2004","unstructured":"Tomlinson JW, Walker EA, Bujalska IJ, Draper N, Lavery GG, Cooper MS et al. 11\u00df-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831\u2013866.","journal-title":"Endocr Rev"},{"key":"BFtp201367_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0960-0760(91)90107-G","volume":"38","author":"L Linberg","year":"1991","unstructured":"Linberg L, Wang JZ, Arison BH, Ulick S . Synthesis of a deuterium-labeled cortisol for the study of its rate of 11-beta-hydroxy dehydrogenation in man. J Steroid Biochem Mol Biol 1991; 38: 351\u2013357.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"BFtp201367_CR4","first-page":"277","volume":"87","author":"R Andrew","year":"2002","unstructured":"Andrew R, Smith K, Jones GC, Walker BR . Distinguishing the activities of 11\u00df-hydroxysteroid dehydrogenases in vivo using isotopically labeled cortisol. J Clin Endocrinol Metab 2002; 87: 277\u2013285.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtp201367_CR5","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2337\/diabetes.53.8.2051","volume":"53","author":"R Basu","year":"2004","unstructured":"Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson CM, Toffolo G et al. Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-\u00df hydroxysteroid dehydrogenase (11\u00df-HSD) type 1 pathway. Diabetes 2004; 53: 2051\u20132059.","journal-title":"Diabetes"},{"key":"BFtp201367_CR6","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2337\/diabetes.54.5.1364","volume":"54","author":"R Andrew","year":"2005","unstructured":"Andrew R, Westerbacka J, Wahren J, Yki-J\u00e4rvinen H, Walker BR . The contributions of visceral adipose tissue to splanchnic cortisol production in healthy humans. Diabetes 2005; 54: 1364\u20131370.","journal-title":"Diabetes"},{"key":"BFtp201367_CR7","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1210\/jc.2004-2390","volume":"90","author":"R Basu","year":"2005","unstructured":"Basu R, Singh RJ, Basu A, Chittilapilly EG, Johnson MC, Toffolo G et al. Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans. J Clin Endocrinol Metab 2005; 90: 3919\u20133926.","journal-title":"J Clin Endocrinol Metab"},{"key":"BFtp201367_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2337\/diabetes.55.03.06.db05-1335","volume":"55","author":"R Basu","year":"2006","unstructured":"Basu R, Singh R, Basu A, Johnson CM, Rizza RA . Effect of nutrient ingestion on total-body and splanchnic cortisol production in humans. Diabetes 2006; 55: 667\u2013674.","journal-title":"Diabetes"},{"key":"BFtp201367_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2337\/db08-1079","volume":"58","author":"R Basu","year":"2009","unstructured":"Basu R, Basu A, Grudzien M, Jung P, Jacobsen P, Johnson M et al. Liver is the site of splanchnic cortisol production in obese nondiabetic humans. Diabetes 2009; 58: 39\u201345.","journal-title":"Diabetes"},{"key":"BFtp201367_CR10","first-page":"135","volume":"18","author":"PC White","year":"1997","unstructured":"White PC, Mune T, Agarwal AK . 11\u00df-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Revi 1997; 18: 135\u2013156.","journal-title":"Endocr Revi"},{"key":"BFtp201367_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1081\/CRP-120023849","volume":"20","author":"SS Jhee","year":"2003","unstructured":"Jhee SS, Zarotsky V . Safety and tolerability of serial cerebrospinal fluid collections during pharmacokinetic\/pharmacodynamic studies: 5 years of experience. Clin Res Regul Aff 2003; 20: 357\u2013363.","journal-title":"Clin Res Regul Aff"},{"key":"BFtp201367_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jalz.2011.05.900","volume":"8","author":"J Li","year":"2012","unstructured":"Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS et al. Effect of human cerebrospinal fluid sampling frequency on amyloid-\u03b2 levels. Alzheimer\u2019s Dement 2012; 8: 295\u2013303.","journal-title":"Alzheimer\u2019s Dement"},{"key":"BFtp201367_CR13","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1046\/j.1365-2265.1996.00853.x","volume":"45","author":"M Palermo","year":"1996","unstructured":"Palermo M, Shackleton CHL, Mantero F, Stewart PM . Urinary free cortisone and the assessment of 11\u00df-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol 1996; 45: 605\u2013611.","journal-title":"Clin Endocrinol"},{"key":"BFtp201367_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s002280050260","volume":"52","author":"M Bergstr\u00f6m","year":"1997","unstructured":"Bergstr\u00f6m M, Westerberg G, N\u00e9meth G, Traut M, Gross G, Greger G et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur J Clin Pharmacol 1997; 52: 121\u2013128.","journal-title":"Eur J Clin Pharmacol"},{"key":"BFtp201367_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/npp.2009.167","volume":"35","author":"JS Fowler","year":"2010","unstructured":"Fowler JS, Logan J, Azzaro AJ, Fielding RM, Zhu W, Poshusta AK et al. Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology 2010; 35: 623\u2013631.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp201367_CR16","first-page":"1618","volume":"46","author":"NMT Freedman","year":"2005","unstructured":"Freedman NMT, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using 11C-L-deprenyl and PET. J Nuclear Med 2005; 46: 1618\u20131624.","journal-title":"J Nuclear Med"},{"key":"BFtp201367_CR17","first-page":"506","volume":"85","author":"J Hirvonen","year":"2009","unstructured":"Hirvonen J, Kailaj\u00e4rvi M, Haltia T, Koskimies S, N\u00e5gren K, Virsu P et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: A dose-finding study with a novel MAO-B inhibitor, EVT 301. ClinPharmacol Therap 2009; 85: 506\u2013512.","journal-title":"ClinPharmacol Therap"},{"key":"BFtp201367_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/1098-2396(200104)40:1<19::AID-SYN1022>3.0.CO;2-7","volume":"40","author":"HM Ruottinen","year":"2001","unstructured":"Ruottinen HM, Niinivirta M, Bergman J, Oikonen V, Solin O, Eskola O et al. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson\u2019s disease requires prolonged imaging. Synapse 2001; 40: 19\u201326.","journal-title":"Synapse"},{"key":"BFtp201367_CR19","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1212\/WNL.56.3.408","volume":"56","author":"H Shinotoh","year":"2001","unstructured":"Shinotoh H, Aotsuka A, Fukushi K, Nagatsuka S, Tanaka N, Ota T et al. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 2001; 56: 408\u2013410.","journal-title":"Neurology"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/tp201367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/tp201367","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp201367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T21:53:14Z","timestamp":1672955594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp201367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,27]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2013,8]]}},"alternative-id":["BFtp201367"],"URL":"https:\/\/doi.org\/10.1038\/tp.2013.67","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,27]]},"assertion":[{"value":"11 September 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors designed, conducted and analyzed the study as employees or contractors of AbbVie. The decision to publish was approved with research management and legal review at AbbVie. Rita Basu was paid as an independent consultant during the design of the study. Hakop Gevorkian, Stanford S Jhee and Larry Ereshefsky are employees of California Clinical Trials Medical Group or PAREXEL International, organizations that were contracted by AbbVie to conduct the study. David A Katz, Wei Liu, Charles Locke, Peer Jacobson, Diane M Barnes, Guohua An, Matthew J Rieser, Dan Daszkowski, Frances Groves, Gerard Heneghan, Ajay Shah and Gerard J. Marek are (or were at the time of the study) employees of AbbVie and may own AbbVie stock or options.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}